Biohaven Ltd.
BHV-1400
IgA Nephropathy
Resolved
98days ago
Phase 2 readout · Mar 31, 2026
What's at stake
Phase 2 trial results for BHV-1400 in IgA Nephropathy are due Mar 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“A pivotal study is set to initiate in the first quarter of 2026.”